Invikafusp Alfa Plus Sacituzumab Govitecan Generates Responses in Metastatic TNBC and HR+/HER2– Breast Cancer
A phase 1b/2 trial showed a 28% ORR in TNBC and 25% in HR+/HER2– breast cancer patients treated with invikafusp alfa and sacituzumab govitecan. The combination demonstrated preliminary antitumor activity with no new safety signals. Sacituzumab govitecan is FDA-approved for these indications. The trial's lead author noted the potential for deeper immune responses in historically resistant tumors.
How this was made
The 30-second read
Why it matters
The data provide the first efficacy signal for invikafusp alfa, potentially expanding Gilead's oncology portfolio.
Market read
New trial data could influence GILD valuation and signal activity in the ADC/T‑cell agonist space.
What to watch
Safety signals such as cytokine release syndrome in 85% of patients could limit broader adoption.
Background
Phase 1b/2 interim results presented at the 2026 SITC Annual Meeting for a novel dual T‑cell agonist combined with an existing ADC.
Ticker impact
Gilead's sacituzumab govitecan (Trodelvy) is part of the new Phase 1b/2 STARt-002 trial showing early antitumor activity.
likely upward pressure as the market prices in the encouraging trial data
First‑report interim data with ORR 25‑28% and manageable safety suggest expanded indication, a material catalyst for GILD.
Market effects
May boost broader ADC and T‑cell agonist biotech sector as investors seek similar pipelines.
US biotech market could see modest gains; European peers likely unaffected.
Limited to oncology drug development community.
Counterpoint
Early data are from a small, single‑arm study; efficacy may not translate to larger trials, risking disappointment.
Key entities
- CompanyGilead Sciences
Manufacturer of sacituzumab govitecan (Trodelvy).
- DrugInvikafusp Alfa (STAR0602)
First‑in‑class dual T‑cell agonist under investigation.
